MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:36Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Topical corticosteroids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #182

2026-05-23T03:56:08Z

parser-claude batch MedTemplate pre-fill, Top 300 #182

New page

{{MedTemplate
| generic = Hydrocortisone (cortisol)
| brand = Cortef (oral), Solu-Cortef (IV), many topical brands (Cortizone, OTC); Plenadren, Alkindi (modified-release for adrenal insufficiency)
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid (short-acting, with mineralocorticoid activity)]], [[:Category:Topical_corticosteroids|Topical corticosteroid]]
| uses = <vote slug="adrenal-insufficiency-use">Adrenal insufficiency (primary, secondary, congenital)</vote>, <vote slug="adrenal-crisis-use">Adrenal crisis (IV)</vote>, <vote slug="topical-dermatitis-use">Mild inflammatory dermatoses (topical, OTC at 1%)</vote>, <vote slug="autoimmune-stress-dose-use">Stress-dose coverage perioperatively in chronic steroid users</vote>
| starting_dose = Physiologic replacement 15-25 mg/d divided (e.g., 10 mg AM, 5 mg noon, 5 mg afternoon); stress dose 50-100 mg IV q6-8h; adrenal crisis 100 mg IV then 50-100 mg q6h; topical 0.5-2.5% applied 2-4×/d
| preparations = 5, 10, 20 mg oral tablets; 100, 250, 500, 1000 mg IV (Solu-Cortef); 0.5%, 1%, 2.5% topical creams/ointments; rectal foam and enemas
| fda_max = Indication-specific
| pill_id =
| routes = Oral, IV, IM, topical, rectal
| onset = Hours
| duration = Biologic ~8-12 hours (short-acting)
| halflife = Plasma ~1-2 hours; biologic ~8-12 hours<ref name="cortef-label">FDA Prescribing Information, Cortef (hydrocortisone), Pfizer/Pharmacia, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/008697s045,008141s073lbl.pdf</ref>
| bioavailability = ~96% (oral)<ref name="cortef-label" />
| pregnancy = Use when benefits outweigh; widely used at physiologic doses for adrenal insufficiency.{{citation needed}}
| legal = OTC (low-dose topicals) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
| mechanism = <vote slug="hydrocortisone-mech-claim">Hydrocortisone is bioidentical cortisol; at physiologic doses it provides glucocorticoid replacement in adrenal insufficiency, and at pharmacologic doses it produces broad anti-inflammatory and immunosuppressive effects via the glucocorticoid receptor.</vote> Unlike synthetic analogs like dexamethasone, hydrocortisone retains substantial mineralocorticoid activity, which is the source of the dose-dependent sodium retention and BP effects but also why it is the most physiologic single agent for primary adrenal insufficiency (when paired with fludrocortisone for additional mineralocorticoid coverage)<ref name="cortef-label" />.
}}

== References ==
<references />

Hydrocortisone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #182